SBC Medical added to membership of Russell 3000® Index
IRVINE, Calif.--(BUSINESS WIRE)--Jun 27, 2025--
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/
Yoshiyuki Aikawa-Director (Chairman), CEO
Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.
For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website.
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.
For more information, visit https://sbc-holdings.com/
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at www.sec.gov.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608244276/en/
CONTACT: SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail:[email protected] LLC (In the US)
Bill Zima / Managing Partner Email:[email protected]
KEYWORD: SOUTHEAST ASIA SINGAPORE NORTH AMERICA ASIA PACIFIC JAPAN EUROPE UNITED STATES UNITED KINGDOM CALIFORNIA
INDUSTRY KEYWORD: MEDICAL SUPPLIES TECHNOLOGY PROFESSIONAL SERVICES OTHER HEALTH HEALTH HEALTH TECHNOLOGY MEDICAL DEVICES COSMETICS RETAIL DATA ANALYTICS SOFTWARE
SOURCE: SBC Medical Group Holdings Incorporated
Copyright Business Wire 2025.
PUB: 06/27/2025 07:30 PM/DISC: 06/27/2025 07:31 PM
http://www.businesswire.com/news/home/20250608244276/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Nvidia Stock: Buy at the Current High?
Nvidia stock has surged 1,500% over the past five years -- and this week it reached a record high. The company has shown its strengths in the high-growth area of artificial intelligence, and that's translated into soaring revenue. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has proven itself to be at the center of the artificial intelligence (AI) revolution. The company designs the most sought-after AI chips to power the performance of AI models and has expanded into a full range of AI products and services, from networking to enterprise software and even a new compute marketplace offering. All of these efforts have helped Nvidia's earnings roar higher, and the company ended the latest fiscal year at a record revenue level of $130 billion. To further illustrate the pace of growth, investors only have to look back two years. Then, Nvidia's annual revenue totaled $27 billion. Nvidia clearly has been a winner in this AI boom. This victory extends to stock price performance, with the shares climbing a jaw-dropping 1,500% over the past five years to reach a new high this week. Now the logical question is: Should you buy Nvidia at this high or wait for a lower entry point? Nvidia has played and surely will continue to play a pivotal role in the AI story. Nvidia sells the most powerful graphics processing units (GPUs) on the market and has designed a variety of other products to accompany them. So customers, for example, might use Nvidia GPUs along with its high-speed connection NVLink so processors can share data. Customers may opt for Nvidia application software to build AI agents and various AI workflows, or the company's infrastructure software to manage processes. And just recently, Nvidia launched DGX Cloud Lepton, a marketplace where developers can access GPUs from a variety of connected cloud providers. Thanks to its innovation throughout the AI universe, Nvidia has made itself an almost unavoidable option for most companies aiming to develop and apply AI to their businesses. Importantly, Nvidia also has been first to market with many of its products and services, allowing it to take the lead, and its ongoing innovation and this effort to continually offer customers more service options may keep it there. It's no surprise that all of this has resulted in soaring earnings -- rising in the double- and triple-digit percentages -- and high profitability on sales. Nvidia has maintained gross margin exceeding 70% during most quarters, only declining to 60% in the recent quarter due to a charge linked to lost sales in China. This leads me to the main risk to Nvidia right now, and that is its presence in that particular market, one that made up 13% of sales last year. The U.S. has imposed controls on exports of chips to China, blocking Nvidia's access to that market. The move prompted Nvidia to remove China from its sales forecasts due to being unable to predict what might happen. Nvidia surely would see higher growth if it could sell chips to China, but even without that market, growth is solid. It's important to remember that U.S. customers actually make up nearly half of Nvidia's total sales. Even in the worst scenario -- zero sales in China -- Nvidia's AI growth story remains bright. Even with growth going strong and the future looking bright, investors might wonder if buying Nvidia now, at a new high, is a good idea. The stock trades for 35 times forward earnings estimates, higher than a few weeks ago, but lower than a peak of more than 50 just a few months ago. Considering Nvidia's earnings track record, market position, and future prospects, this looks like a reasonable price -- even if it's not at the dirt cheap levels of a few weeks ago. Of course, stocks rarely rise in one straight line, so there very well could be a dip in the weeks or months to come, offering an even more enticing entry point. But it's very difficult to time the market and get in at any stock's lowest point. It's a better idea to buy at a reasonable price and hold on for the long term. And here's why: Nvidia's gains or losses over a period of weeks or one quarter, for example, won't make much of a difference in your returns if you hold onto the stock for several years. That's why you don't necessarily have to worry about buying at the high when you're a long-term investor, as long as the stock's valuation is fair. That's the case of top AI stock Nvidia right now, making it a buy -- even at the high. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Nvidia Stock: Buy at the Current High? was originally published by The Motley Fool
Yahoo
34 minutes ago
- Yahoo
Atascadero reveals its brand-new downtown. ‘This is what we've been waiting for'
After a year of construction on the city's main drag, downtown Atascadero has a whole new look. Just in time for summer, residents can now enjoy a fully renovated El Camino Real with added car and bike parking, lush greenery and trees, hanging street lights, a center road divider, pedestrian cross walks and other safe and sustainable features. The renovations span the main drag of El Camino Real from Rosario Avenue to Highway 41. 'This isn't a thoroughfare anymore,' city manager Jim Lewis told reporters. 'This is the center of downtown.' The city celebrated the completion of its downtown safety, parking and beautification efforts on Friday with a city-wide block party. The event kicked off with a ribbon-cutting ceremony at 5 p.m. followed by an evening of live music, disco ball scavenger hunts and dance performances in the streets. Local businesses kept their doors open later than usual to accommodate customers into the night. 'Atascadero really is the genuine, authentic community in our county,' Lewis said. 'Atascadero is the living room for our county. We're not pretentious, we're not overrun by visitors, and we have free parking. And so this is just the icing on the cake of why we want local people to hang out here in Atascadero. And I think this is what we've been waiting for.' Atascadero is in middle of massive downtown renovation. But is construction slowing business? With construction on the El Camino Real Downtown Safety and Parking Enhancement Project commencing last June, the $12 million public works project clocked in on time and on budget. Much of the project's funding came from state and federal grants, as well as contributions from the San Luis Obispo Council of Governments. The project added nearly 130 new free parking spots to downtown and safe crosswalks at the city's most risky intersections on El Camino Real. The bulk of the work was completed by Friday, with only some landscaping, sidewalk paving and streetlamp installation still to be done in downtown north of Traffic Way in the coming weeks. Two grand entry arches resembling the original city sign, which was blue with neon white letters, will be installed on either end of the new downtown center in the fall.
TechCrunch
38 minutes ago
- TechCrunch
Meta reportedly hires four more researchers from OpenAI
In Brief Looks like Meta isn't done poaching talent from OpenAI. Earlier this week, TechCrunch reported that Meta had hired influential OpenAI researcher Trapit Bansal, and according to The Wall Street Journal, it also hired three other researchers from the company. Now The Information is reporting four more Meta hires from OpenAI: Researchers Shengjia Zhao, Jiahui Yu, Shuchao Bi, and Hongyu Ren. This hiring spree comes after the April launch of Meta's Llama 4 AI models, which reportedly did not perform as well as CEO Mark Zuckerberg had hoped. (The company was also criticized over the version of Llama that it used for a popular benchmark.) There's been some back-and-forth between the two companies, with OpenAI CEO Sam Altman suggesting that Meta was offering '$100 million signing bonuses' while adding that 'so far, none of our best people' have left. Meta CTO Andrew Bosworth then told employees that while senior leaders may have been offered that kind of money, 'the actual terms of the offer' were more complex than a simple one-time signing bonus.
